UnitedHealth's Financials Recover, But Stock Price Lags Behind

UnitedHealth's stock has been underperforming despite its improving financials. The company has seen a tangible margin recovery, particularly in Medicare and Optum Health segments. However, Commercial remains a weak spot.

The recent guidance update showed a boost in operating earnings and an improved medical care ratio. This signals progress for the company, despite ongoing challenges in Medicaid and Commercial segments.

UnitedHealth's valuation is reasonable at 17.8x NTM P/E, but its upside relies on continued margin normalization rather than top-line growth or multiple expansion.